Danièle Marceau

Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang YH, Lee JL, Sarwar N, Haas NB, Gurney H, Sawrycki P, Mahave M, Gross-Goupil M, Zhang T, Burke JM, Doshi G, Melichar B, Kopyltsov E, Alva A, Oudard S, Topart D, Hammers H, Kitamura H, McDermott DF, Silva A, Winquist E, Cornell J, Elfiky A, Burgents JE, Perini RF, Powles T,

Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma

N Engl J Med, 390 (15), 2024.

Résumé | Liens:

Heymach JV, Harpole D, Mitsudomi T, Taube JM, Hochmair M, Winder T, Zukov R, Garbaos G, Gao S, Kuroda H, Ostoros G, Tran TV, You J, Lee KY, Antonuzzo L, Papai-Szekely Z, Akamatsu H, Biswas B, Spira A, Crawford J, Le HT, Aperghis M, Doherty GJ, Mann H, Fouad TM, Reck M,

Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer

N Engl J Med, 389 (18), 2023.

Résumé | Liens:

Bégin P, Callum J, Jamula E, Cook R, Heddle NM, Tinmouth A, Zeller MP, Beaudoin-Bussières G, Amorim L, Bazin R, Loftsgard KC, Carl R, Chassé M, Cushing MM, Daneman N, Devine DV, Dumaresq J, Fergusson DA, Gabe C, Glesby MJ, Li N, Liu Y, McGeer A, Robitaille N, Sachais BS, Scales DC, Schwartz L, Shehata N, Turgeon AF, Wood H, Zarychanski R, Finzi A, , Arnold DM

Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial

Nat Med, 27 (11), 2021.

Résumé | Liens:

Patriquin CJ, Kiss T, Caplan S, Chin-Yee I, Grewal K, Grossman J, Larratt L, Marceau D, Nevill T, Sutherland DR, Wells RA, Leber B

How we treat paroxysmal nocturnal hemoglobinuria: A consensus statement of the Canadian PNH Network and review of the national registry

Eur J Haematol, 102 (1), 2019.

Résumé | Liens:

Bordeleau S, Poitras J, Marceau D, Breton C, Beaupre P, Archambault PM

Use of prothrombin complex concentrate in warfarin anticoagulation reversal in the emergency department: a quality improvement study of administration delays

BMC Health Serv Res, 15 , 2015.

Résumé | Liens:

Yan J, Marceau D, Drouin R

Tetrasomy 8 is associated with a major cellular proliferative advantage and a poor prognosis. two cases of myeloid hematologic disorders and review of the literature

Cancer Genet Cytogenet, 125 (1), 2001.

Résumé | Liens: